David J. Gagnon

David J. Gagnon

Auto-generated profile, based on publicly available information

David J. Gagnon

Department of Pharmacy, Maine Medical Center, Portland, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 November 2017 in Critical Care
Verified
Journal Article
Open access
PDF file
LPLauren E. Payne
Lauren E. Payne
DGDavid J. Gagnon
David J. Gagnon
RRRichard R. Riker
Richard R. Riker
DSDavid B. Seder
David B. Seder
EGElizabeth K. Glisic
Elizabeth K. Glisic
GFGilles L. Fraser
Gilles L. Fraser
Cefepime is a widely used antibiotic with neurotoxicity attributed to its ability to cross the blood–brain barrier and exhibit concentration-dependent ϒ-aminobutyric acid (GABA) antagonism. Neurotoxic symptoms include depressed consciousness, encephalopathy, aphasia, myoclonus, seizures, and coma. Data suggest that up to 15% of ICU patients treated with cefepime may experience these adverse effects. Risk factors include renal dysfunction, excessive dosing, preexisting brain injury, and elevated serum cefepime concentrations. We aimed to characterize the clinical course of cefepime neurotoxicity and response to interventions. A librarian-assisted search identified publications describing cefepime-associated neurotoxicity from January 1980 to February 2016 using the CINAHL and MEDLINE databases. Search terms included cefepime, neurotoxicity, encephalopathy, seizures, delirium, coma, non-convulsive status epilepticus, myoclonus, confusion, aphasia, agitation, and death. Two reviewers independently assessed identified articles for eligibility and used the Preferred Reporting Items for Systematic review and Meta-Analysis Protocols (PRISMA-P) for data reporting. Of the 123 citations identified, 37 (representing 135 patient cases) were included. Patients had a median age of 69 years, commonly had renal dysfunction (80%) and required intensive care (81% of patients with a reported location). All patients exhibited altered mental status, with reduced consciousness (47%), myoclonus (42%), and confusion (42%) being the most common symptoms. All 98 patients (73% of cohort) with electroencephalography had abnormalities, including non-convulsive status epilepticus (25%), myoclonic status epilepticus (7%), triphasic waves (40%), and focal sharp waves (39%). As per Food and Drug Administration (FDA)-approved dosing guidance, 48% of patients were overdosed; however, 26% experienced neurotoxicity despite appropriate dosing. Median cefepime serum and cerebrospinal fluid (CSF) concentrations were 45 mg/L (n = 21) and 13 mg/L (n = 4), respectively. Symptom improvement occurred in 89% of patients, and 87% survived to hospital discharge. The median delay from starting the drug to symptom onset was 4 days, and resolution occurred a median of 2 days after the intervention, which included cefepime discontinuation, antiepileptic administration, or hemodialysis. Cefepime-induced neurotoxicity is challenging to recognize in the critically ill due to widely varying symptoms that are common in ICU patients. This adverse reaction can occur despite appropriate dosing, usually resolves with drug interruption, but may require additional interventions such as antiepileptic drug administration or dialysis.

24 March 2015 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Verified
Journal Article
Closed access
PDF file
DGDavid J. Gagnon
David J. Gagnon
RRRichard R. Riker
Richard R. Riker
EGElizabeth K. Glisic
Elizabeth K. Glisic
AKAndrew Kelner
Andrew Kelner
HPHilary M. Perrey
Hilary M. Perrey
GFGilles L. Fraser
Gilles L. Fraser

1 February 2017 in Journal of Critical Care
Verified
Journal Article
Closed access
DGDavid J. Gagnon
David J. Gagnon
GFGabriel V. Fontaine
Gabriel V. Fontaine
KSKathryn E. Smith
Kathryn E. Smith
RRRichard R. Riker
Richard R. Riker
RMRussell R. Miller
Russell R. Miller
GFGilles L. Fraser
Gilles L. Fraser

1 July 2015 in Resuscitation
Verified
Journal Article
Closed access
DGDavid J. Gagnon
David J. Gagnon
NNNiklas Nielsen
Niklas Nielsen
GFGilles L. Fraser
Gilles L. Fraser
RRRichard R. Riker
Richard R. Riker
JDJohn Dziodzio
John Dziodzio
DSDavid B. Seder
David B. Seder

20 May 2020 in Neurocritical Care
Verified
Journal Article
Open access
PDF file
ALAngela M. Leclerc
Angela M. Leclerc
RRRichard R. Riker
Richard R. Riker
CBCaitlin S. Brown
Caitlin S. Brown
TMTeresa May
Teresa May
KNKristina Nocella
Kristina Nocella
DGDavid J. Gagnon
David J. Gagnon
Background/Objective Neurostimulants may improve or accelerate cognitive and functional recovery after intracerebral hemorrhage (ICH), ischemic stroke (IS), or subarachnoid hemorrhage (SAH), but few studies have described their safety and effectiveness in the intensive care unit (ICU). The objective of this study was to describe amantadine and modafinil administration practices during acute stroke care starting in the ICU and to evaluate safety and effectiveness. Methods Consecutive adult ICU patients treated with amantadine and/or modafinil following acute non-traumatic IS, ICH, or SAH were evaluated. Neurostimulant administration data were extracted from the electronic medication administration record, including medication (amantadine, modafinil, or both), starting dose, time from stroke to initiation, and whether the neurostimulant was continued at hospital discharge. Patients were considered responders if they met two of three criteria within 9 days of neurostimulant initiation: increase in Glasgow coma scale (GCS) score ≥ 3 points from pre-treatment baseline, improved wakefulness or participation documented in caregiver notes, or clinical improvement documented in physical or occupational therapy notes. Potential confounders of the effectiveness assessment and adverse drug effects were also recorded. Results A total of 87 patients were evaluable during the 3.7-year study period, including 41 (47%) with ICH, 29 (33%) with IS, and 17 (20%) with SAH. The initial neurostimulant administered was amantadine in 71 (82%) patients, modafinil in 13 (15%), or both in 3 (3%) patients. Neurostimulants were initiated a median of 7 (4.25, 12.75) days post-stroke (range 1–27 days) for somnolence (77%), not following commands (32%), lack of eye opening (28%), or low GCS (17%). The most common starting dose was 100 mg twice daily for both amantadine (86%) and modafinil (54%). Of the 79 patients included in the effectiveness evaluation, 42 (53%) were considered responders, including 34/62 (55%) receiving amantadine monotherapy and 8/24 (33%) receiving both amantadine and modafinil at the time they met the definition of a responder. No patient receiving modafinil monotherapy was considered a responder. The median time from initiation to response was 3 (2, 5) days. Responders were more frequently discharged home or to acute rehabilitation compared to non-responders (90% vs 62%, p = 0.006). Among survivors, 63/72 (88%) were prescribed a neurostimulant at hospital discharge. The most common potential adverse drug effect was sleep disruption (16%). Conclusions Neurostimulant administration during acute stroke care may improve wakefulness. Future controlled studies with a neurostimulant administration protocol, prospective evaluation, and discretely defined response and safety criteria are needed to confirm these encouraging findings.

12 May 2020 in Neurocritical Care
Verified
Journal Article
Closed access
PDF file
DGDavid J. Gagnon
David J. Gagnon
ALAngela M. Leclerc
Angela M. Leclerc
RRRichard R. Riker
Richard R. Riker
CBCaitlin S. Brown
Caitlin S. Brown
TMTeresa May
Teresa May
DSDavid B. Seder
David B. Seder